CRP and type 2 diabetes mellitus: In this context, the administration of sitagliptin in patients with T2DM reduces the expression of pro-inflammatory markers such as Nuclear Factor kappa B (NF-kB) transcription factor, C-Reactive Protein (CRP), and Interleukin (IL)-6 [16].